Here are 1-3 brief analogies for Penumbra:

• Medtronic for neurovascular and peripheral vascular medical devices.

• Meta's Oculus, but for medical rehabilitation and physical therapy.

• Stroke Management Devices: Catheter-based systems, including aspiration catheters and stent retrievers, designed to remove blood clots from the brain in patients experiencing ischemic stroke.
• Aneurysm and Hemorrhagic Stroke Devices: Coils, embolization systems, and access technologies used to treat brain aneurysms and other neurovascular conditions involving bleeding.
• Peripheral Vascular Thrombectomy Devices: Catheter-based systems for removing blood clots from arteries and veins in the limbs, lungs, and other peripheral regions to treat conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Embolization Devices: Systems used for therapeutic embolization, which intentionally blocks blood vessels to treat conditions such as tumors, arteriovenous malformations, and uterine fibroids.
• Immersive Healthcare (VR Training): Virtual reality platforms and modules that provide realistic simulations for medical training and education, particularly for interventional procedures.

Penumbra, Inc. (PEN) primarily sells its innovative medical devices to other companies and healthcare institutions, rather than directly to individuals.

Due to the nature of the medical device industry and Penumbra's diversified sales strategy, the company does not publicly disclose specific major customer companies by name that account for a significant portion of its revenue (e.g., greater than 10%) in its financial filings. Their customer base is broadly distributed across the global healthcare system.

However, Penumbra's products are purchased by the following categories of organizations:

• Hospitals and Healthcare Systems: These are the primary end-users of Penumbra's devices, including large hospital networks, academic medical centers, and community hospitals, both public and private.
• Clinics and Ambulatory Surgical Centers: Smaller healthcare facilities that perform specialized procedures utilizing Penumbra's tools.
• Third-Party Distributors: In various international markets, Penumbra utilizes distributors to reach healthcare providers. These companies act as intermediaries, purchasing products from Penumbra for resale to the end-users.

As no single specific major customer company is publicly identified or represents a material concentration of revenue for Penumbra, no specific company names or their stock symbols can be listed.

null

Adam Elsesser, Chairman and Chief Executive Officer

Adam Elsesser co-founded Penumbra in 2004 and has served as CEO since its inception, and as Chairman of the Board since January 2015. Prior to Penumbra, Mr. Elsesser was CEO of SMART Therapeutics, Inc., a medical device company focused on neuro-intervention, from 2000 to 2002. Following its acquisition by Boston Scientific Corporation, he served as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, he was a partner in the law firm of Shartsis Friese LLP.

Maggie Yuen, Chief Financial Officer

Maggie Yuen has been the Chief Financial Officer of Penumbra since 2019. She has over 20 years of experience in scaling finance organizations, processes, and infrastructure within the manufacturing, medical devices, and life science industries. Ms. Yuen previously held various leadership positions at Thermo Fisher Scientific Inc., where she was the Vice President of Finance for the Genetic Science Division, and at Mirion Technologies, Boston Scientific, Glu Mobile, and Johnson & Johnson.

Shruthi Narayan, President

Shruthi Narayan was appointed President of Penumbra, effective September 1, 2025. With 20 years of experience in the medical device industry, she joined Penumbra in 2013 and has led significant growth in both neuro and vascular franchises. Ms. Narayan previously served as president of Penumbra's interventional business and began her medical device career at Medtronic in 2006, where she worked in engineering, regulatory affairs, and cardiovascular sales.

Arani Bose, M.D., Chief Innovator and Director

Dr. Arani Bose co-founded Penumbra with Adam Elsesser in 2004 and has served as its Chief Innovator since 2004. He was also Chairman of the Board and Chief Medical Officer from 2005 to 2015. Prior to founding Penumbra, Dr. Bose co-founded SMART Therapeutics, Inc. while an Assistant Professor of Radiology and Neurology at New York University (NYU) School of Medicine, where he also had a clinical practice from 1997 to 2004. At Smart Therapeutics, Dr. Bose developed and led clinical trials for the Neuroform Stent and Wingspan Stent, leading to their FDA approval.

Johanna Roberts, Executive Vice President, General Counsel and Secretary

Johanna Roberts serves as the Executive Vice President, General Counsel, and Secretary for Penumbra. She started at Penumbra, Inc. in July 2016. No detailed background information regarding founding/managing other companies, selling companies, or private equity firm backing was found in the search results for Ms. Roberts.

The key risks to Penumbra's business include:

1. Regulatory and Legal Risks, including Product Recalls and Litigation: Penumbra operates in a highly regulated industry, facing stringent domestic and foreign medical device regulations that can impede product approvals, lead to recalls, or result in litigation. A significant example is the recall of the Penumbra Jet 7 Xtra Flex Catheter due to reports of device failure, severe injury, and patient deaths, which has led to ongoing lawsuits alleging defective devices and failure to warn about risks. The U.S. Food and Drug Administration (FDA) designated this as a Class I recall, its most serious classification.
2. Intense Competition: Penumbra faces a highly competitive landscape within the medical device industry from both large, well-capitalized companies like Boston Scientific, Medtronic, and Stryker, as well as smaller firms specializing in niche products. This competition can impact Penumbra's market share, pricing power, and profitability, necessitating continuous investment in product development and marketing to maintain its competitive edge.
3. Dependence on Core Product Lines and Risk of Technological Obsolescence: While Penumbra benefits from an innovative product portfolio, particularly in thrombectomy and embolization devices, there is a risk associated with over-reliance on these core product lines. Furthermore, the medical device industry is characterized by rapid technological advancements, posing a constant threat of obsolescence to existing products and requiring Penumbra to continuously innovate to meet evolving healthcare needs.

Penumbra's Addressable Markets:

• Neurovascular Devices (Global): The global neurovascular devices market was estimated at approximately $3.02 billion in 2024 and is projected to reach around $6.64 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 8.20% from 2025 to 2034. Other estimates place the global market at $7.37 billion in 2024, growing to $12.94 billion by 2034 with a CAGR of 5.79%, or $3.32 billion in 2024, projected to reach $7.01 billion by 2035 with a CAGR of 7.02%.
• Neurovascular Devices (U.S.): The U.S. neurovascular devices market size was approximately $655.34 million in 2024 and is predicted to be worth around $1,474.58 million by 2034, rising at a CAGR of 8.34% from 2024 to 2034. North America dominated the global market with a revenue share of 31% in 2024.
• Peripheral Vascular Devices (Global): The global peripheral vascular devices market size was estimated at $10.44 billion in 2024 and is projected to reach $16.90 billion by 2033, growing at a CAGR of 5.3% from 2025 to 2033. Another report valued the market at $12.2 billion in 2023, expecting it to reach $20.8 billion by 2033 with a CAGR of 5.6% from 2024 to 2033.
• Peripheral Vascular Devices (North America): North America held the largest revenue share of the global market at 38.92% in 2024. North America leads the Peripheral Vascular Devices Market with a 40% largest share. The U.S. peripheral vascular devices market is anticipated to register the fastest growth rate during the forecast period.
• Thrombectomy Devices (Global): The global thrombectomy devices market was valued at $1.64 billion in 2024 and is projected to reach $3.29 billion by 2034, expanding at a CAGR of 7.21% from 2025 to 2034. Other estimates indicate the market was $1.75 billion in 2025, set to reach $2.46 billion by 2030 with a CAGR of 7.07%, or $1.64 billion in 2024, anticipated to reach $2.9 billion by 2032 with a CAGR of 7.41%.
• Thrombectomy Devices (U.S.): The U.S. thrombectomy devices market size was estimated at $450 million in 2024 and is predicted to be worth around $920 million by 2034, at a CAGR of 7.41% from 2025 to 2034.
• Pulmonary Embolism Market (Global): The global pulmonary embolism market size was calculated at $2.15 billion in 2024 and is projected to hit approximately $4.78 billion by 2034, undergoing a CAGR of 8.32% during the forecast period 2025-2034.
• Immersive Healthcare (Virtual Reality for rehabilitation and mental health): null. Penumbra announced in August 2024 that it would "permanently discontinue" its Immersive Healthcare business.

Penumbra (symbol: PEN) is anticipated to drive future revenue growth over the next 2-3 years through several key factors:

1. Continued Strength and Innovation in U.S. Thrombectomy: Penumbra projects robust growth in its U.S. thrombectomy business, with guidance of 20%-21% growth for 2025. This is fueled by increasing adoption and market penetration of its Computer Assisted Vacuum Thrombectomy (CAVT) portfolio, including advanced products like Lightning Flash 2.0 and Lightning Bolt 7.
2. Launch and Expansion of New Products: The company has a pipeline of innovative products expected to contribute significantly to revenue. Key examples include the upcoming launch of Thunderbolt, a CAVT system for stroke, and the recently introduced Ruby XL embolization platform, which is already driving growth in the embolization and access business. Other notable launches include the ACCESS25 Delivery Microcatheter for aneurysm access, the SwiftSET Neuro Embolization Coil, and the Element Vascular Access System for venous thromboembolism treatments.
3. Accelerated Growth in the Embolization and Access Business: Penumbra has seen accelerated growth in its embolization and access segment, particularly in the U.S. This is attributed to successful new product introductions, such as Ruby XL, and strategic investments in expanding its dedicated sales team for this area.
4. International Market Expansion and Easing Headwinds: After some mixed trends, Penumbra expects international growth to rebound in the second half of 2025, with a focus on materially increasing both revenues and profitability in these markets in the coming years. The easing of headwinds in the China region is also identified as a catalyst for renewed international revenue growth in 2026.
5. Positive Outcomes from Clinical Trials: Favorable results from significant clinical trials, such as the STORM-PE trial evaluating the Indigo Mechanical Aspiration device for pulmonary embolism, are expected to further drive broader clinical adoption of Penumbra's technologies and reinforce their efficacy, thereby contributing to revenue growth.

Share Repurchases

• In August 2024, Penumbra's Board of Directors authorized a share repurchase program of up to $200 million, set to expire on July 31, 2025.
• As part of this authorization, Penumbra entered into a $100 million accelerated share repurchase (ASR) agreement in August 2024.
• As of December 31, 2024, $100 million remained available under the authorized repurchase program.

Share Issuance

• In May 2020, Penumbra announced the pricing of an underwritten public offering of 753,012 shares of its common stock at a price of $166.00 per share.
• The net proceeds from this 2020 offering were intended for general corporate purposes, including working capital, product development, and potential acquisitions.

Outbound Investments

• In September 2021, Penumbra completed the acquisition of Sixense Enterprises Inc. for approximately $250 million.

Capital Expenditures

• For the last 12 months as of December 31, 2024, Penumbra's capital expenditures amounted to approximately $19.46 million.
• Strategic capital investments have included the establishment of facilities like the Costa Rica facility, aimed at supporting global market expansion.
• The company's capital expenditure ratio, at approximately 1.7% of revenue, is noted to be lower than the medical device industry average of 5-10%.